We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: atezolizumab
MedXY News
EnglishTag

atezolizumab

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial
newsatezolizumabclinical trial

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

By MedXY|Jul 14, 2026

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Gastroenterology
atezolizumab
bevacizumab

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma

By MedXY|May 10, 2026

A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without i

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial
newsatezolizumabimmunotherapy

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial

By MedXY|Jan 13, 2026

The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profil

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial
Clinical UpdatesatezolizumabBCG

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

By MedXY|Jan 9, 2026

The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit
newsatezolizumabbevacizumab

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit

By MedXY|Dec 8, 2025

Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma
newsatezolizumabbevacizumab

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study
newsatezolizumabdurvalumab

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study

By MedXY|Oct 29, 2025

A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial
newsatezolizumabbevacizumab

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

By MedXY|Oct 28, 2025

A recent phase II trial demonstrates lenvatinib’s efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial
Oncologyatezolizumabclinical trial

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY|Oct 25, 2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes
OncologyatezolizumabctDNA

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

By MedXY|Oct 25, 2025

This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immun

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial
Clinical Updatesatezolizumabimmunotherapy

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY|Oct 1, 2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic

Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications
Clinical Updatesatezolizumabcabozantinib

Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications

By MedXY|Oct 1, 2025

The CONTACT-02 phase 3 trial shows cabozantinib plus atezolizumab improves progression-free survival but not overall survival in advanced mCRPC post-ARPI, offering a novel non-androgen receptor-based option.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities